• PLAC1 Targeting in Clear Cell Renal Cell Carcinoma

  2026-09-20

  A 2025 Cellular Signalling study identifies PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma (ccRCC). By combining TCGA analysis, protein-level validation, PLAC1 knockdown, and high-throughput virtual screening, the researchers nominate Amaronol B and Canagliflozin as compounds that reduce PLAC1-associated ccRCC progression in vitro.

• Trametinib (GSK1120212): Assay Reliability

  2026-09-19

  This scenario-driven guide shows how Trametinib (GSK1120212), SKU A3018, can help researchers interpret variable viability, proliferation, and cytotoxicity results through mechanism-aware experimental design. It covers model selection, DMSO stock preparation, pathway-confirming readouts, heterogeneity, and practical vendor evaluation.

• BI-1347: CDK8 Signaling Workflow Guide

  2026-09-18

  BI-1347 is a potent, selective small-molecule probe for testing target-dependent signaling and antitumor biology. This workflow translates CDK8/19-focused findings from osteoarthritis research into practical cell-based, inflammatory, transcriptomic, and translational assay designs.

• Nilotinib (AMN-107) Assay Workflows

  2026-09-18

  Build more informative kinase-response experiments with Nilotinib (AMN-107), from BCR-ABL target engagement to separate measurements of growth arrest and cell death. This workflow combines practical dosing guidance, mutation-aware comparisons, and troubleshooting for chronic myeloid leukemia research and KIT-driven models.

• CUDC-907: Practical Dual PI3K/HDAC Workflow

  2026-09-17

  CUDC-907 provides a research tool for examining concurrent PI3K/AKT signaling pathway inhibition and histone deacetylase inhibition in controlled cancer cell assays. This guide covers preparation, exposure, controls, and endpoint QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or clinical applications.

• RSL3: A Context-Aware GPX4 Assay Strategy

  2026-09-17

  RSL3 is a glutathione peroxidase 4 inhibitor that can reveal how metabolic state controls ferroptosis sensitivity. This guide uses bladder cancer MCT4 research to build a more discriminating assay and interpretation framework for cancer biology.

• Trametinib: From MEK Inhibition to Neural ERK Biology

  2026-09-16

  Trametinib (GSK1120212) is more than an oncology pathway probe: it can help dissect how oxidative signals reach ERK1/2 in sensory neurons. This article connects MEK inhibition, BH4-derived H2O2 signaling, and assay design while defining the translational limits of cross-domain interpretation.

• SR-202: PPARγ Antagonist Workflow Guide

  2026-09-16

  SR-202 enables controlled inhibition of PPARγ to separate receptor-dependent adipogenesis, metabolic signaling, and macrophage responses from nonspecific cell effects. This workflow guide connects validated PPARγ biology with practical assay design for insulin resistance research, obesity research, and hypothesis-driven immunometabolic studies.

• Pseudo-UTP for Smarter mRNA Synthesis

  2026-09-15

  Pseudo-UTP enables controlled replacement of UTP during in vitro transcription to support more persistent, efficiently translated RNA. This practical guide connects nucleotide substitution with mRNA vaccine development, assay design, quality control, and troubleshooting.

• Regorafenib, RRM2, and Melanoma Progression

  2026-09-15

  The 2024 iScience study identifies RRM2 as a mechanistic downstream target through which Regorafenib suppresses melanoma cell growth, invasion, and metastasis. Its combination of RNA sequencing, functional perturbation, pathway analysis, and in vivo validation provides a useful framework for studying multikinase inhibitor responses beyond angiogenesis.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-14

  Borchert et al. linked homologous recombination repair defects, including BAP1-associated BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integrated cell-line and clinical-sample strategy supports molecular stratification of mesothelioma while emphasizing that the findings remain preclinical and require prospective validation.

• Ruxolitinib, DRP1, and ATC Cell Death

  2026-09-14

  A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, apoptosis, and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its in vitro and in vivo findings position transcriptional control of mitochondrial dynamics as an important component of ruxolitinib activity in this aggressive tumor context.

• Nocodazole as a Translational Cell-Cycle Probe

  2026-09-13

  Nocodazole is more than a mitotic-arrest reagent: its reversible control of β-tubulin and microtubule dynamics can help translational researchers connect cytoskeletal state, mitotic progression, cap-dependent translation, and cancer phenotypes. This article presents a mechanism-led framework for experimental validation, assay design, reagent selection, and preclinical interpretation.

• Ganetespib: From Hsp90 Mechanism to Assay Insight

  2026-09-12

  Ganetespib and STA-9090 offer a powerful framework for studying Hsp90-dependent tumor biology. This article connects its cancer research applications with a landmark norovirus secretion study to show how causal, orthogonal assay design can improve mechanistic interpretation.

• Troglitazone: From PPARγ Biology to SPP1 Strategy

  2026-09-11

  Troglitazone offers a useful PPARγ-centered research entry point for connecting lipid and glucose metabolism with tumor-myeloid biology. This thought-leadership article translates SPP1-focused macrophage screening into a rigorous strategy for testing whether nuclear-receptor perturbation can reprogram SPP1-high tumor-associated macrophages without confusing hypothesis with established evidence.

7732 records 1/516 page Next 12345 下5页 Last page